title: Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM).
  
  
  METHODS
  Retrospective, multicenter, consecutive, nonrandomized, interventional case series.
  
  
  METHODS
  Twenty-six eyes of 26 patients with CNV secondary to pathologic myopia; 11 eyes with previous photodynamic therapy; and 15 eyes with no previous treatment.
  
  
  RESULTS
  3 or more months. Best-corrected visual acuity (BCVA), ocular coherence tomography, and the presence of metamorphopsia were assessed monthly.
  
  
  RESULTS
  At 1 month, 31% of the eyes had an improvement in visual acuity of 3 or more lines. Twenty-six eyes completed 3 months of follow-up, and nine eyes completed 6 months of follow-up. Visual acuity improved significantly from 20/100 at baseline to 20/80 at 1 month (P = 0.003) to 20/63 at 3 months (P < 0.001), and 20/50 at 6 months (P = 0.01). A significant reduction in ocular coherence tomography central thickness was observed at 1, 3, and 6 months. No cases of severe visual acuity loss occurred, and no systemic or ocular side effects were registered during the follow-up.
  
  
  CONCLUSIONS
  Short-term results of intravitreal ranibizumab for myopic CNV are encouraging. Further prospective long-term studies are necessary to evaluate safety and efficacy of intravitreal ranibizumab in the treatment of myopic CNV.
authors.affiliation: Department of Ophthalmology, University Hospital of Coimbra, Portugal. rufino.silva@oftalmologia.co.pt
authors.forename: Rufino M
authors.initials: RM
authors.lastname: Silva
authors.forename: José M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: João
authors.initials: J
authors.lastname: Nascimento
authors.forename: Angela
authors.initials: A
authors.lastname: Carneiro
authors.forename: Paulo
authors.initials: P
authors.lastname: Rosa
authors.forename: Augusto
authors.initials: A
authors.lastname: Barbosaa
authors.forename: Fausto
authors.initials: F
authors.lastname: Carvalheira
authors.forename: J Rui Faria
authors.initials: JR
authors.lastname: Abreu
authors.forename: José G
authors.initials: JG
authors.lastname: Cunha-Vaz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D000069579:Ranibizumab; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab